抑藻菌株Bacillus sp.hsn03分离鉴定及其对铜绿微囊藻的抑制效果与特征

【背景】蓝藻常形成水华,严重破坏水生环境及威胁水生生物。微生物能够专一性地抑制蓝藻的生长,从而可以被用于蓝藻水华的控制。【目的】分离筛选一株对有害水华藻——铜绿微囊藻(Microcystisaeruginosa)7806有高效抑藻能力的菌株,对其进行生理生化和分子鉴定,并研究其抑藻效果与特征。【方法】通过API试剂条确定其生理生化特征,对细菌的16SrRNA基因进行测序并构建系统进化树,通过探究细菌菌体、上清、发酵液的抑藻效果确定该菌的抑藻方式,通过测定不同温度、pH、蛋白酶K、有机溶剂萃取和透析条件下的抑藻效果及傅里叶红外光谱来确定胞外抑藻物质的性质。【结果】菌株hsn03与芽孢杆菌属(Bacillus sp.)的Bacillus sonorensis NBRC101234有最高相似性,达99.59%;通过分泌胞外抑藻物质对铜绿微囊藻生长表现出抑制效果,且最佳抑藻添加量为7.0%(体积比);胞外抑藻物质为一类分子量大于500 Da且小于1 kD,耐高温,耐酸碱,含有叁键和累积双键,非蛋白、多糖类的小分子物质。【结论】抑藻菌株的挖掘与鉴定对于丰富有害藻华藻的抑藻菌质资源有非常大的促进作用,通过对抑藻方式、效果和特征的研究为进一步将抑藻菌应用于铜绿微囊藻的治理奠定基础。国家自然科学基金(51008119,41576109);;河南师范大学国家级科研项目培育基金(5101049170805)~

微生物絮凝剂对小球藻细胞氧化应激研究

小球藻作为能源藻,可以提供产生物柴油,但是小球藻生物质的获取成为能源藻发展的瓶颈.目前研究藻细胞生物质收集的方法很多,但不同收集方法对能源藻细胞的氧化应激研究却很少.分别研究絮凝功能细菌xn-1所产生物絮凝物质和离心法对能源藻——小球藻生物质在收集过程中对藻细胞的氧化应激,以期确定絮凝微生物对小球藻细胞的生物安全性.采用涂布划线法从藻际分离纯化絮凝功能微生物;通过梯度醇沉法获得絮凝物质;分别用絮凝微生物所分泌絮凝物质和离心法收集藻细胞生物质,并对藻细胞内蛋白含量、总糖含量、丙二醛含量(MDA)、过氧化氢酶(CAT)活性、谷胱甘肽(GSH)含量和抗坏血酸(AsA)含量进行测定;以分光光度计测定其吸光度值.经过测定并经过统计学显著性分析,发现离心作用下收集的藻细胞内的MDA,GSH和AsA含量显著高于利用絮凝物质絮凝得到的藻细胞.离心作用相对于絮凝作用造成藻细胞膜发生更高的脂质过氧化,产生大量的活性氧自由基,诱导非酶抗氧化系统响应.因此,离心法收集藻生物质相对于微生物絮凝对藻细胞的伤害更大,絮凝微生物比离心法更适合于收集能源藻生物质.国家自然科学基金(51008119;41576109);;河南省高等学校重点科研项目计划(17A610002

Gravitational wave detection by space laser interferometry

为印证广义相对论和开拓引力波天文学窗口,引力波探测是当前国际研究热点.本文围绕空间激光干涉引力波探测,对其科学意义、发展状况、关键技术等进行了回顾.与地面激光干涉引力波探测相比,空间探测的工作频段更低,从10~(-4)~10Hz,在工作距离为百万公里量级上,预计能探测到双致密星系统、超大质量比双黑洞绕转系统、中等质量比双黑洞绕转系统,以及星系合并引起的超大质量黑洞并合等波源.为此,测距精度须达到皮米的量级,并且保证测距技术有效工作的无拖曳航天技术亦有很高的要求.本文以欧洲的空间激光引力波探测计划为例,主要对上述两项技术进行分析和阐述,并展望了空间引力波探测在我国的发展趋势和前景

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials